MAPT and Alzheimer disease: If validated, blood tau could complement or reduce the reliance on CSF and tau-PET-based imaging, thereby enhancing diagnostic accuracy, improving accessibility, and supporting more effective disease monitoring and prognosis in AD [14,15].